Company Filing History:
Years Active: 2005
Title: **James Peter Anduiza: Pioneering Innovations in Heart Valve Technology**
Introduction
James Peter Anduiza is an accomplished inventor based in Costa Mesa, California. He is particularly known for his groundbreaking work in the field of cardiac devices, specifically his innovative percutaneously deliverable heart valve prosthesis. With his expertise in medical engineering, Anduiza has made significant contributions to healthcare.
Latest Patents
Anduiza holds a patent for a percutaneously deliverable heart valve prosthesis and its method of delivery. This invention provides a solution for patients with diseased heart valves, enabling effective replacement in a less invasive manner. The prosthesis is designed to be anchored to the valvular annulus of the patient, offering a transition from a low-profile, flexible state during delivery to a rigid, expanded position post-delivery. This capability ensures that the device withstands the strong recoil forces exerted by a stenosed valve orifice.
Career Highlights
Currently, Anduiza is affiliated with 3F Therapeutics, Inc., where he leverages his skills to develop innovative medical devices. His work has not only led to advances in heart valve technology but also improved patient outcomes in cardiac care. Throughout his career, he has remained dedicated to innovation in the medical field, pushing the boundaries of traditional practices.
Collaborations
In the course of his work, Anduiza collaborates with talented colleagues such as Rodolfo C Quijano and Hosheng Tu. Together, they contribute to the mission of advancing medical technology and improving patient care through innovation. Their teamwork and shared vision foster an environment where groundbreaking ideas can flourish.
Conclusion
James Peter Anduiza exemplifies the spirit of innovation and dedication within the medical technology sector. His patented percutaneously deliverable heart valve prosthesis is a testament to his commitment to improving healthcare solutions. As he continues his work at 3F Therapeutics, Inc., he remains a key figure in advancing technologies that enhance the quality of life for patients with heart conditions.